Source data for the Viral hepatitis elimination barometer among people who inject drugs in Europe

This data bundle contains all source data used on the page, Viral hepatitis elimination barometer among people who inject drugs in Europe

All data tables are made available in CSV format. Tables are presented first with their individual methodological notes. A bulk download version is also available further down this page.

All tables in CSV format with methodological notes.

Method of estimation
TM: treatment multiplier; CR: capture-recapture; TP: truncated Poisson; CM: combined methods; HM: HIV multiplier; MM: mortality multiplier; MIM: multivariate indicator method; OT: other

The level of evidence is assessed separately for seroprevalence studies (SP) and routine diagnostic tests (DT), based on the case definition for people who inject drugs, sample size, type of settings, number of sites, type of biological sample. SP are also assessed for sampling method; and DT for timeliness, periodicity and geographical coverage.

Average of available studies (63.30 per 1000 people)

The level of evidence is assessed separately for seroprevalence studies (SP) and routine diagnostic tests (DT), based on the case definition for people who inject drugs, sample size, type of settings, number of sites, type of biological sample. SP are also assessed for sampling method; and DT for timeliness, periodicity and geographical coverage.

Average of available studies (60.64 per 1000 people)

The level of evidence is assessed separately for seroprevalence studies (SP) and routine diagnostic tests (DT), based on the case definition for people who inject drugs, sample size, type of settings, number of sites, type of biological sample. SP are also assessed for sampling method; and DT for timeliness, periodicity and geographical coverage.

Average of available studies (37.87 %)

The level of evidence is assessed separately for seroprevalence studies (SP) and routine diagnostic tests (DT), based on the case definition for people who inject drugs, sample size, type of settings, number of sites, type of biological sample. SP are also assessed for sampling method; and DT for timeliness, periodicity and geographical coverage.

Average of available studies (5.20 %)

The level of evidence is assessed separately for seroprevalence studies (SP) and routine diagnostic tests (DT), based on the case definition for people who inject drugs, sample size, type of settings, number of sites, type of biological sample. SP are also assessed for sampling method; and DT for timeliness, periodicity and geographical coverage.

Average of available studies (2.76 %)

The coverage is based on the latest national estimates of injecting drug use and high-risk opioid use matched by harm reduction activity data (within a maximum of 2 years). The estimate of coverage of opioid agonist treatment for Belgium is derived from a subnational study conducted in 2019.

WHO 2020 target for needles and syringe distribution per person who injects drugs = 200

WHO 2020 the proportion of high-risk opioid users receiving opioid agonist treatment = 0.4

WHO 2020 target for the proportion of high-risk opioid users receiving opioid agonist treatment = 0.4

WHO 2020 target for needles and syringe distribution per person who injects drugs = 200

Top